Lifeline Therapeutics Names James D. Crapo, M.D. to Board of Directors; Company Welcomes World-Renowned Scientist to Ranks.

DENVER -- Lifeline Therapeutics, Inc. (OTCBB:LFLT), a health and nutrition company that is dedicated to extending "healthy life expectancy" through better antioxidant therapies, today announced that Dr. James D. Crapo will be joining the company's Board of Directors. Dr. Crapo brings nearly 30 years of experience in the health and science field to his new role. He served as the Chairman of Medicine at the National Jewish Medical and Research Center, from 1996, until his recent sabbatical in 2004.

National Jewish is a top-rated private institution in immunology and allergic diseases and has been rated number one nationally in pulmonary medicine by U.S. News and World Report for the past 7 years.

"We are thrilled to welcome Dr. Crapo to our Board of Directors," said Bill Driscoll, President and CEO of Lifeline Therapeutics. "His extensive work in antioxidant research, particularly with Superoxide Dismutase (SOD), will provide additional insight into fighting both oxidative stress and aging - two key areas in which we hope to further research in an effort to better the lives of millions of people around the world."

Dr. Crapo maintains a large research program focused on the role of oxidants and anti-oxidants in the causation and treatment of diseases. He was the first scientist to extend Dr. Fridovich and Dr. McCord's (Director of Science for Lifeline Therapeutics) original discovery of SOD to mammalian models of disease. SOD is the body's most powerful natural antioxidant.

Prior to coming to National Jewish, Dr. Crapo spent over 15 years as the Chief of the Pulmonary and Critical Care Medicine Division at Duke University Medical Center. Throughout his professional career he has been active in numerous professional societies, including service on the NHLBI Advisory Council and serving as President of the American Thoracic Society and President of the Fleischner Society.

Dr. Crapo said, "I have been involved in antioxidant research for decades. Lifeline's Protandim represents a significant breakthrough that has far-reaching implications and applications. I am truly excited to be involved with such promising research and products."

Dr. Crapo has authored more than 200 original scientific publications, numerous book chapters and seven textbooks.

Recent Publications

Piganelli JD, SC Flores, C Cruz, J Koepp, I Batinic-Haberle, J
Crapo, B Day, R Kachadourian, R Young, B Bradley and K Haskins. A
metalloporphyrin-based superoxide dismutase mimic inhibits adoptive
transfer of autoimmune diabetes by a diabetogenic T-cell clone.
Diabetes 51:347-355, 2002.

Smith KR, DL Uyeminami, UP Kodavanti, JD Crapo, L-Y Chang and KE
Pinkerton. Inhibition of tobacco smoke-induced lung inflammation by a
catalytic antioxidant. Free Radic Biol Med 33:1106-1114, 2002.

Bowler RP, H Sheng, JJ Enghild, RD Pearlstein, DS Warner and JD
Crapo. A catalytic antioxidant (AEOL 10150) attenuates expression of
inflammatory genes in stroke. Free Radic Biol Med 33:1141-1152, 2002.

Kinnula VL, Crapo JD. Superoxide dismutases in the lung and human
lung diseases. Am J Respir Crit Care Med. 2003 Jun 15;167(12):1600-19.
Review.

Bowler RP, Arcaroli J, Abraham E, Patel M, Chang LY, Crapo JD.
Evidence for extracellular superoxide dismutase as a mediator of
hemorrhage-induced lung injury. Am J Physiol Lung Cell Mol Physiol.
2003 Apr;284(4):L680-7. Epub 2003 Jan 10.

Chang LY, Subramaniam M, Yoder BA, Day BJ, Ellison MC, Sunday ME,
Crapo JD. A catalytic antioxidant attenuates alveolar structural
remodeling in bronchopulmonary dysplasia. Am J Respir Crit Care Med.
2003 Jan 1;167(1):57-64.

Bowler RP, Crapo JD. Oxidative stress in allergic respiratory
diseases. J Allergy Clin Immunol. 2002 Sep;110(3):349-56.

Chang LY, Crapo JD. Inhibition of airway inflammation and
hyperreactivity by an antioxidant mimetic. Free Radic Biol Med. 2002
Aug 1;33(3):379-86.

For a list of all publications since 1986, click here.

ABOUT LIFELINE THERAPEUTICS

Lifeline Therapeutics, Inc. is a publicly-traded company (OTCBB:LFLT) based in Denver, Colorado, that is dedicated to the manufacture, marketing and distribution of therapies that promote "healthy life expectancy." The Company is initially focusing exclusively on unique antioxidant products under its Protandim brand and in the future will develop an array of product candidates for nutraceutical, pharmaceutical and cosmeceutical applications. To underscore the Company's commitment to higher quality of life and healthy life expectancy, Lifeline Therapeutics has pledged 10% of its pre-tax profits to support orphanages and other global humanitarian needs.

Except for historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and applicable common law. These statements involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein. Further, the Company operates in industries where securities values may be volatile and may be influenced by regulatory and other factors beyond the Company's control. Other important factors that the Company believes might cause such differences include the Company's limited cash flow and the rapid development of technology, lack of liquidity for the Company's common stock, working capital shortages, the length of time for scientific advances to reach the market (if they ever reach the market), among other risks. In assessing forward-looking statements contained herein, readers are urged to carefully read all cautionary statements contained in the Company's filings with the Securities and Exchange Commission.